国际最新研究：减重药物或影响与食物渴望相关的脑信号

Core Insights - A recent study published in the journal Nature Medicine indicates that the drug tirzepatide (brand name Mounjaro), used for diabetes and weight management, can suppress brain activity related to food cravings in individuals with eating disorders over several months [1] Group 1: Drug Mechanism and Effects - Tirzepatide is a GLP-1 receptor agonist that promotes weight loss, but its effects on the brain networks regulating eating disorders require further investigation [1] - The study involved three obese participants with uncontrolled eating habits, revealing that heightened low-frequency brain signals (delta-theta activity) in the nucleus accumbens correlate with excessive food cravings [1] Group 2: Treatment and Outcomes - Therapeutic deep brain stimulation in two participants reduced delta-theta signals and food focus, suggesting a biological marker for food cravings [2] - A third participant, who underwent weight loss surgery and used tirzepatide for diabetes management, also experienced reduced food cravings and weight loss, although delta-theta activity re-emerged after several months of continued tirzepatide use [2] Group 3: Research Implications - The authors highlight the potential of tirzepatide in treating eating disorders by influencing brain signal biomarkers related to food cravings [2] - Further research is necessary to explore the relationship between tirzepatide, excessive food focus, and brain activity [2]